Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oltipraz for Liver Fat Reduction in NAFLD
NCT02068339Phase 3Completed
- Sponsor
- PharmaKing
- Start
- Feb 2014
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of oltipraz in non-alcoholic fatty liver disease (NAFLD), sponsored by PharmaKing. Started Feb 2014; status: completed.
02
Drugs
oltipraz
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02068339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02068339.